aTYR PHARMA INC
No SEC Form 4 filings for $ATYR in the last 30 days.
See all $ATYR insider activity →aTYR PHARMA INC (ATYR) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On October 16, 2026, aTyr Pharma, Inc. (the “Company”) held its 2026 Special Meeting of Stockholders (the “Special Meeting”). As of September 4, 2026, the record date for the Special Meeting (the “Record Date”), 98,08
aTyr Pharma (NASDAQ:ATYR) published research on its experimental therapy ATYR0101 in the Journal of Biological Chemistry. The study showed ATYR0101 reduced collagen content and Ashcroft score in a lung fibrosis model, outperforming nintedanib. The company plans to advance ATYR0101 into clinical trials in 2027. ATYR0101 targets fibrosis by inducing myofibroblast apoptosis, according to the research.
aTyr Pharma (NASDAQ:ATYR) reached an agreement with the FDA on the Phase 3 study protocol for efzofitimod, a treatment for pulmonary sarcoidosis. The trial will enroll 372 patients and evaluate lung function and patient-reported outcomes. The company needs additional funding and has $58.9M in cash as of June 30. Shares were down 6.08% to $0.35 at the time of publication.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning ATYR (aTYR PHARMA INC). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent ATYR coverage spans corporate actions, regulation and technology.
The approved reverse split will reduce share count and increase per‑share price, potentially improving liquidity and attracting institutional investors.
The positive preclinical results could boost investor confidence ahead of IND filing and future trials.
Regulatory alignment clears a key hurdle, likely supporting near‑term share price stability and potential upside if trial progresses.
Positive regulatory milestone likely to lift the stock further as the trial timeline becomes clearer.
The FDA alignment clears a key regulatory hurdle, potentially de‑risking the Phase 3 trial and supporting future financing opportunities.
AlphAI scores every news story that mentions ATYR with an AI model for sentiment and relevance, and aggregates insider trades from aTYR PHARMA INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
aTYR PHARMA INC (ATYR) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On October 16, 2026, aTyr Pharma, Inc. (the “Company”) held its 2026 Special Meeting of Stockholders (the “Special Meeting”). As of September 4, 2026, the record date for the Special Meeting (the “Record Date”), 98,08
1 min readaTyr Pharma (NASDAQ:ATYR) published research on its experimental therapy ATYR0101 in the Journal of Biological Chemistry. The study showed ATYR0101 reduced collagen content and Ashcroft score in a lung fibrosis model, outperforming nintedanib. The company plans to advance ATYR0101 into clinical trials in 2027. ATYR0101 targets fibrosis by inducing myofibroblast apoptosis, according to the research.
2 min readaTyr Pharma (NASDAQ:ATYR) reached an agreement with the FDA on the Phase 3 study protocol for efzofitimod, a treatment for pulmonary sarcoidosis. The trial will enroll 372 patients and evaluate lung function and patient-reported outcomes. The company needs additional funding and has $58.9M in cash as of June 30. Shares were down 6.08% to $0.35 at the time of publication.
2 min readaTyr Pharma (ATYR) stock rose 9.1% in pre-market trading after aligning with the FDA on a Phase 3 study protocol for efzofitimod, its lead therapeutic candidate. The study, expected to start in Q4 2026, will evaluate efzofitimod in patients with pulmonary sarcoidosis. The company's stock has faced uncertainty but maintains a Buy rating from analysts.
2 min readaTYR PHARMA INC (ATYR) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On September 24, 2026, aTyr Pharma, Inc. (the Company) announced that it has reached alignment with the U.S. Food and Drug Administration (FDA) on the protocol for a Phase 3 study of its lead therapeutic candidate, efzofitimod, in patients with chronic, sy
2 min readUniverse Pharmaceuticals (UPC) rose 34.89% after-hours due to multiple Schedule 13G filings. BioAffinity (BIAF) explores new uses for its CyPath Lung test, up 3%. Modular Medical (MODD) gained 7% after announcing a product launch. MAIA (MAIA) rose 6% following an insider purchase. Telix (TLX) completed a Phase 3 study, up 2.21%. aTyr Pharma (ATYR) awaits FDA response, up 4%.
2 min readaTyr (LIFE) appointed Brandon Yaras as CFO. City Therapeutics, Cue Biopharma (CUE), Longeveron (LGVN), Olema Oncology (OLEM), and Stuart Therapeutics made CFO appointments. Sanofi (SNY) expanded its CFO's role to include business operations and M&A.
3 min readBiopharma roundup reported FDA/EC approvals and trial updates for Lantheus (LNTH) TAUKLARIFY, Ceribell (CBLL) AI EEG algorithms, Labcorp (LH) PGDx CDx, and EU/UK approvals for Galderma (GDERF) Restylane Shaype and Rhythm (RYTM) IMCIVREE. GRAIL (GRAL) faces an FDA panel on Sept. 23. Teledyne (TDY) to buy Varex (VREX) for about $1.1B; Aura (AURA) cut 20% staff.
7 min readaTYR PHARMA INC (ATYR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Contact: Ashlee Dunston Sr. Director, Investor Relations and Public Affairs adunston@atyrpharma.com aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD Company awaiting comments f
4 min readaTYR PHARMA INC (ATYR) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. Exhibit 99.1 TERMINATION AGREEMENT This TERMINATION AGREEMENT (this “ Agreement ”) is made and entered into as of July 30, 2026 (“ Execution Date ”), by and between aTyr Pharma, Inc., a Delaware corporation, having its principal place of business at 10240 Sorrento Valley Road, Su
6 min read
